Latest News

Immix and Nexcella Make Progress in US Trial for Light Chain Amyloidosis CAR-T NXC-201
Immix and Nexcella Make Progress in US Trial for Light Chain Amyloidosis CAR-T NXC-201

October 6th 2024

NEXICART-2 has moved on to its expansion cohort after completing dosing of patients in its initial cohort.

CGTLive®’s Weekly Rewind
CGTLive®’s Weekly Rewind – October 4, 2024

October 4th 2024

Data Roundup: September 2024 Features Updates in Ophthalmology Gene Therapy, CAR-T for Lymphoma, and More
Data Roundup: September 2024 Features Updates in Ophthalmology Gene Therapy, CAR-T for Lymphoma, and More

October 4th 2024

First Patient Dosed Achieves Complete Response in Estrella Immunopharma’s Trial for CD19-Targeted T-cell Therapy EB103 in B-Cell Lymphomas
First Patient Dosed Achieves Complete Response in Estrella Immunopharma’s Trial for CD19-Targeted T-cell Therapy EB103 in B-Cell Lymphomas

October 3rd 2024

Daniel Hart, PhD, the senior director and head of technology development at Epic Bio
CRISPR-Mediated In Vivo Epigenomic Activation

October 3rd 2024

Video Interviews

Conference Coverage

View All
Daniel Hart, PhD, the senior director and head of technology development at Epic Bio
CRISPR-Mediated In Vivo Epigenomic Activation

October 3rd 2024

Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
Arun Upadhyay, PhD, on Results from IRD Gene Therapy OCU400’s Phase 1/2 Trial

September 30th 2024

Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
Arun Upadhyay, PhD, on the Potential of Gene Therapy in Inherited Retinal Disease

September 26th 2024

Beacon Therapeutics’ XLRP Gene Therapy AGTC-501 Continues to Show Favorable Benefit-Risk Profile at 36 Months
Beacon Therapeutics’ XLRP Gene Therapy AGTC-501 Continues to Show Favorable Benefit-Risk Profile at 36 Months

September 24th 2024

All News

© 2024 MJH Life Sciences

All rights reserved.